Photodynamic Therapy Alone Versus Combined With Intravitreal Bevacizumab for Age-related Macular Degeneration

K

Kumamoto University

Status

Completed

Conditions

Age-related Macular Degeneration

Treatments

Drug: Bevacizumab

Study type

Interventional

Funder types

Other

Identifiers

NCT01032109
PCBK610

Details and patient eligibility

About

The purpose of this study is to compare 12-month results of two single initial treatments-photodynamic therapy with verteporfin alone and this therapy combined with intravitreal bevacizumab-for neovascular age-related macular degeneration, not including patients with polypoidal choroidal vasculopathy who were presumed to have age-related macular degeneration.

Enrollment

45 patients

Sex

All

Ages

50+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • choroidal neovascularization caused by age-related macula degeneration
  • no previous treatment
  • a follow-up at least 12 months
  • a baseline visual acuity ranging from a letter score of 0 to 70 on the Early Treatment Diabetic Retinopathy Study chart

Exclusion criteria

  • choroidal neovascularization caused by other eye diseases
  • ocular surgery within the past 3 mouths
  • history of uveitis
  • intraocular pressure higher than 25 mmHg, or glaucoma
  • history of systemic or ocular thromboembolic events.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

45 participants in 1 patient group

Bevacizumab
Experimental group
Treatment:
Drug: Bevacizumab

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems